-
Something wrong with this record ?
An evaluation of therapeutic and reactivating effects of newly developed oximes (K156, K203) and commonly used oximes (obidoxime, trimedoxime, HI-6) in tabun-poisoned rats and mice
J Kassa, J Karasova, K Musilek, K Kuca
Language English Country Ireland
Document type Comparative Study
- MeSH
- Acetylcholinesterase blood metabolism MeSH
- Antidotes administration & dosage chemistry therapeutic use MeSH
- Atropine administration & dosage chemistry therapeutic use MeSH
- Cholinesterase Inhibitors administration & dosage chemistry poisoning MeSH
- Species Specificity MeSH
- Financing, Organized MeSH
- Injections, Intramuscular MeSH
- Drug Therapy, Combination MeSH
- Rats MeSH
- Lethal Dose 50 MeSH
- Molecular Structure MeSH
- Mice MeSH
- Obidoxime Chloride administration & dosage chemistry therapeutic use MeSH
- Organophosphates administration & dosage chemistry MeSH
- Organophosphate Poisoning MeSH
- Oximes administration & dosage chemistry therapeutic use MeSH
- Rats, Wistar MeSH
- Pyridinium Compounds administration & dosage chemistry therapeutic use MeSH
- Cholinesterase Reactivators administration & dosage chemistry therapeutic use MeSH
- Toxicity Tests, Acute methods MeSH
- Trimedoxime administration & dosage chemistry therapeutic use MeSH
- Chromatography, High Pressure Liquid MeSH
- Seizures enzymology chemically induced prevention & control MeSH
- Animals MeSH
- Check Tag
- Rats MeSH
- Male MeSH
- Mice MeSH
- Animals MeSH
- Publication type
- Comparative Study MeSH
The potency of newly developed monoxime bispyridinium compounds (K156, K203) in reactivating tabun-inhibited acetylcholinesterase and reducing tabun-induced lethal toxic effects was compared with commonly used oximes (obidoxime, trimedoxime, the oxime HI-6) using in vivo methods. Studies determining percentage of reactivation of tabun-inhibited blood and tissue acetylcholinesterase in poisoned rats showed that the reactivating efficacy of newly developed oxime K203 is comparable with obidoxime and trimedoxime in blood and higher than the reactivating potency of trimedoxime and obidoxime in diaphragm and brain, where the difference in reactivating efficacy of obidoxime, trimedoxime and K203 is significant. On the other hand, the potency of newly developed K156 to reactivate tabun-inhibited acetylcholinesterase is comparable with obidoxime or trimedoxime in diaphragm and brain. It is significantly lower than the reactivating efficacy of trimedoxime and obidoxime in blood. Moreover, both newly developed oximes were found to be relatively efficacious in the reduction of lethal toxic effects in tabun-poisoned mice. Especially, the oxime K203 is able to decrease the acute toxicity of tabun nearly two times. The therapeutic efficacy of K156 and K203 corresponds to their potency to reactivate tabun-inhibited acetylcholinesterase, especially in diaphragm and brain. In contrast to obidoxime and trimedoxime, the oxime HI-6 is not effective in reactivation of tabun-inhibited acetycholinesterase and in reducing tabun lethality. While the oxime K156 does not improve the reactivating and therapeutic effectiveness of currently available obidoxime and trimedoxime, the newly developed oxime K203 is markedly more effective in reactivation of tabun-inhibited acetylcholinesterase in rats, especially in brain, and in reducing lethal toxic effects of tabun in mice and, therefore, it is suitable for the replacement of commonly used oximes for the antidotal treatment of acute tabun poisoning.
References provided by Crossref.org
- 000
- 05205naa 2200769 a 4500
- 001
- bmc11003249
- 003
- CZ-PrNML
- 005
- 20111210202249.0
- 008
- 110225s2008 ie e eng||
- 009
- AR
- 024 __
- $a 10.1016/j.tox.2007.10.015 $2 doi
- 035 __
- $a (PubMed)18054821
- 040 __
- $a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ie
- 100 1_
- $a Kassa, Jiří, $d 1956- $7 mzk2003181395
- 245 13
- $a An evaluation of therapeutic and reactivating effects of newly developed oximes (K156, K203) and commonly used oximes (obidoxime, trimedoxime, HI-6) in tabun-poisoned rats and mice / $c J Kassa, J Karasova, K Musilek, K Kuca
- 314 __
- $a Department of Toxicology, Faculty of Military Health Sciences, Trebesska 1575, 500 01 Hradec Kralove, Czech Republic. kassa@pmfhk.cz
- 520 9_
- $a The potency of newly developed monoxime bispyridinium compounds (K156, K203) in reactivating tabun-inhibited acetylcholinesterase and reducing tabun-induced lethal toxic effects was compared with commonly used oximes (obidoxime, trimedoxime, the oxime HI-6) using in vivo methods. Studies determining percentage of reactivation of tabun-inhibited blood and tissue acetylcholinesterase in poisoned rats showed that the reactivating efficacy of newly developed oxime K203 is comparable with obidoxime and trimedoxime in blood and higher than the reactivating potency of trimedoxime and obidoxime in diaphragm and brain, where the difference in reactivating efficacy of obidoxime, trimedoxime and K203 is significant. On the other hand, the potency of newly developed K156 to reactivate tabun-inhibited acetylcholinesterase is comparable with obidoxime or trimedoxime in diaphragm and brain. It is significantly lower than the reactivating efficacy of trimedoxime and obidoxime in blood. Moreover, both newly developed oximes were found to be relatively efficacious in the reduction of lethal toxic effects in tabun-poisoned mice. Especially, the oxime K203 is able to decrease the acute toxicity of tabun nearly two times. The therapeutic efficacy of K156 and K203 corresponds to their potency to reactivate tabun-inhibited acetylcholinesterase, especially in diaphragm and brain. In contrast to obidoxime and trimedoxime, the oxime HI-6 is not effective in reactivation of tabun-inhibited acetycholinesterase and in reducing tabun lethality. While the oxime K156 does not improve the reactivating and therapeutic effectiveness of currently available obidoxime and trimedoxime, the newly developed oxime K203 is markedly more effective in reactivation of tabun-inhibited acetylcholinesterase in rats, especially in brain, and in reducing lethal toxic effects of tabun in mice and, therefore, it is suitable for the replacement of commonly used oximes for the antidotal treatment of acute tabun poisoning.
- 650 _2
- $a acetylcholinesterasa $x krev $x metabolismus $7 D000110
- 650 _2
- $a testy akutní toxicity $x metody $7 D023382
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a antidota $x aplikace a dávkování $x chemie $x terapeutické užití $7 D000931
- 650 _2
- $a atropin $x aplikace a dávkování $x chemie $x terapeutické užití $7 D001285
- 650 _2
- $a cholinesterasové inhibitory $x aplikace a dávkování $x chemie $x otrava $7 D002800
- 650 _2
- $a reaktivátory cholinesterasy $x aplikace a dávkování $x chemie $x terapeutické užití $7 D002801
- 650 _2
- $a vysokoúčinná kapalinová chromatografie $7 D002851
- 650 _2
- $a kombinovaná farmakoterapie $7 D004359
- 650 _2
- $a injekce intramuskulární $7 D007273
- 650 _2
- $a LD50 $7 D007928
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a myši $7 D051379
- 650 _2
- $a molekulární struktura $7 D015394
- 650 _2
- $a obidoxim chlorid $x aplikace a dávkování $x chemie $x terapeutické užití $7 D009768
- 650 _2
- $a oximy $x aplikace a dávkování $x chemie $x terapeutické užití $7 D010091
- 650 _2
- $a organofosfáty $x aplikace a dávkování $x chemie $7 D010755
- 650 _2
- $a pyridinové sloučeniny $x aplikace a dávkování $x chemie $x terapeutické užití $7 D011726
- 650 _2
- $a krysa rodu Rattus $7 D051381
- 650 _2
- $a potkani Wistar $7 D017208
- 650 _2
- $a záchvaty $x enzymologie $x chemicky indukované $x prevence a kontrola $7 D012640
- 650 _2
- $a druhová specificita $7 D013045
- 650 _2
- $a trimedoxim $x aplikace a dávkování $x chemie $x terapeutické užití $7 D014289
- 650 _2
- $a financování organizované $7 D005381
- 650 _2
- $a otrava organofosfáty $7 D062025
- 655 _2
- $a srovnávací studie $7 D003160
- 700 1_
- $a Žďárová Karasová, Jana, $d 1982- $7 xx0099787
- 700 1_
- $a Musílek, Kamil, $d 1980- $7 xx0135628
- 700 1_
- $a Kuča, Kamil, $d 1978- $7 xx0041831
- 773 0_
- $t Toxicology $w MED00004533 $g Roč. 243, č. 3 (2008), s. 311-316 $x 0300-483X
- 910 __
- $a ABA008 $b x $y 7
- 990 __
- $a 20110413115713 $b ABA008
- 991 __
- $a 20110413115713 $b ABA008
- 999 __
- $a ok $b bmc $g 830602 $s 695242
- BAS __
- $a 3
- BMC __
- $a 2008 $b 243 $c 3 $d 311-316 $i 0300-483X $m Toxicology $n Toxicology $x MED00004533
- LZP __
- $a 2011-2B/ipme